Hepatitis D surgery: Difference between revisions
Jump to navigation
Jump to search
Joao Silva (talk | contribs) |
Joao Silva (talk | contribs) |
||
| Line 11: | Line 11: | ||
===Liver Transplantation=== | ===Liver Transplantation=== | ||
[[Liver transplant]] is indicated in patients with end-stage [[liver disease]], or [[liver failure]] secondary to [[HDV infection]], in whom treatment with [[interferon]] is not indicated.<ref name="pmid23242761">{{cite journal| author=Heidrich B, Manns MP, Wedemeyer H| title=Treatment options for hepatitis delta virus infection. | journal=Curr Infect Dis Rep | year= 2013 | volume= 15 | issue= 1 | pages= 31-8 | pmid=23242761 | doi=10.1007/s11908-012-0307-z | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23242761 }} </ref><ref name="pmid20051970">{{cite journal| author=Wedemeyer H, Manns MP| title=Epidemiology, pathogenesis and management of hepatitis D: update and challenges ahead. | journal=Nat Rev Gastroenterol Hepatol | year= 2010 | volume= 7 | issue= 1 | pages= 31-40 | pmid=20051970 | doi=10.1038/nrgastro.2009.205 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=20051970 }} </ref><ref name="pmid21511329">{{cite journal| author=Hughes SA, Wedemeyer H, Harrison PM| title=Hepatitis delta virus. | journal=Lancet | year= 2011 | volume= 378 | issue= 9785 | pages= 73-85 | pmid=21511329 | doi=10.1016/S0140-6736(10)61931-9 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21511329 }} </ref> These patients usually have a good [[outcome]], with inhibition of [[HBV]] and [[HDV]] reinfection, when simultaneously treated with [[nucleoside]] and [[nucleotide]] analogues, and [[hepatitis B]] [[antibodies]].<ref name="pmid7843702">{{cite journal| author=Samuel D, Zignego AL, Reynes M, Feray C, Arulnaden JL, David MF et al.| title=Long-term clinical and virological outcome after liver transplantation for cirrhosis caused by chronic delta hepatitis. | journal=Hepatology | year= 1995 | volume= 21 | issue= 2 | pages= 333-9 | pmid=7843702 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=7843702 }} </ref> However, [[HDV]] remains latent and can be detected in the new [[liver]] for several months after the [[transplant]]. Therefore prevention of [[HBV]] reinfection should be maintained, in order to simultaneously avoid resurgence of [[HDV]].<ref name="pmid23242761">{{cite journal| author=Heidrich B, Manns MP, Wedemeyer H| title=Treatment options for hepatitis delta virus infection. | journal=Curr Infect Dis Rep | year= 2013 | volume= 15 | issue= 1 | pages= 31-8 | pmid=23242761 | doi=10.1007/s11908-012-0307-z | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23242761 }} </ref> | [[Liver transplant]] is indicated in patients with end-stage [[liver disease]], or [[liver failure]] secondary to [[HDV infection]], in whom treatment with [[interferon]] is not indicated.<ref name="pmid23242761">{{cite journal| author=Heidrich B, Manns MP, Wedemeyer H| title=Treatment options for hepatitis delta virus infection. | journal=Curr Infect Dis Rep | year= 2013 | volume= 15 | issue= 1 | pages= 31-8 | pmid=23242761 | doi=10.1007/s11908-012-0307-z | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23242761 }} </ref><ref name="pmid20051970">{{cite journal| author=Wedemeyer H, Manns MP| title=Epidemiology, pathogenesis and management of hepatitis D: update and challenges ahead. | journal=Nat Rev Gastroenterol Hepatol | year= 2010 | volume= 7 | issue= 1 | pages= 31-40 | pmid=20051970 | doi=10.1038/nrgastro.2009.205 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=20051970 }} </ref><ref name="pmid21511329">{{cite journal| author=Hughes SA, Wedemeyer H, Harrison PM| title=Hepatitis delta virus. | journal=Lancet | year= 2011 | volume= 378 | issue= 9785 | pages= 73-85 | pmid=21511329 | doi=10.1016/S0140-6736(10)61931-9 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21511329 }} </ref> These patients usually have a good [[outcome]], with inhibition of [[HBV]] and [[HDV]] reinfection, when simultaneously treated with [[nucleoside]] and [[nucleotide]] analogues, and [[hepatitis B]] [[antibodies]].<ref name="pmid7843702">{{cite journal| author=Samuel D, Zignego AL, Reynes M, Feray C, Arulnaden JL, David MF et al.| title=Long-term clinical and virological outcome after liver transplantation for cirrhosis caused by chronic delta hepatitis. | journal=Hepatology | year= 1995 | volume= 21 | issue= 2 | pages= 333-9 | pmid=7843702 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=7843702 }} </ref> However, [[HDV]] remains latent and can be detected in the new [[liver]] for several months after the [[transplant]]. Therefore prevention of [[HBV]] reinfection should be maintained, in order to simultaneously avoid resurgence of [[HDV]].<ref name="pmid23242761">{{cite journal| author=Heidrich B, Manns MP, Wedemeyer H| title=Treatment options for hepatitis delta virus infection. | journal=Curr Infect Dis Rep | year= 2013 | volume= 15 | issue= 1 | pages= 31-8 | pmid=23242761 | doi=10.1007/s11908-012-0307-z | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23242761 }} </ref> | ||
- | After [[liver transplantation]] chances of reinfection of the the new [[liver]], may be reduced with administration of [[HBsAg]] [[immunoglobulin]]s. These reduce the levels of [[HBsAg]] in the patient, to a point where [[HDV]] is eliminated.<ref name="pmid9620349">{{cite journal| author=Smedile A, Casey JL, Cote PJ, Durazzo M, Lavezzo B, Purcell RH et al.| title=Hepatitis D viremia following orthotopic liver transplantation involves a typical HDV virion with a hepatitis B surface antigen envelope. | journal=Hepatology | year= 1998 | volume= 27 | issue= 6 | pages= 1723-9 | pmid=9620349 | doi=10.1002/hep.510270636 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=9620349 }} </ref> | ||
==References== | ==References== | ||
Revision as of 12:30, 14 August 2014
|
Hepatitis D |
|
Diagnosis |
|
Treatment |
|
Hepatitis D surgery On the Web |
|
American Roentgen Ray Society Images of Hepatitis D surgery |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: João André Alves Silva, M.D. [2] Jolanta Marszalek, M.D. [3]
Overview
Treatment of hepatitis D does not involve surgery. Some procedures may be indicated in certain complications, such as ascites, in which peritoneal drainage may be performed. End-stage liver disease, liver failure secondary to HDV infection, in patients in which treatment with interferon is not indicated, and hepatocellular carcinoma may require liver transplantation.[1][2]
Surgery
The treatment of hepatitis D does not involve surgical procedures. However, some complications, such as ascites, may require interventional procedures such as peritoneal drainage.
Liver Transplantation
Liver transplant is indicated in patients with end-stage liver disease, or liver failure secondary to HDV infection, in whom treatment with interferon is not indicated.[1][2][3] These patients usually have a good outcome, with inhibition of HBV and HDV reinfection, when simultaneously treated with nucleoside and nucleotide analogues, and hepatitis B antibodies.[4] However, HDV remains latent and can be detected in the new liver for several months after the transplant. Therefore prevention of HBV reinfection should be maintained, in order to simultaneously avoid resurgence of HDV.[1]
After liver transplantation chances of reinfection of the the new liver, may be reduced with administration of HBsAg immunoglobulins. These reduce the levels of HBsAg in the patient, to a point where HDV is eliminated.[5]
References
- ↑ 1.0 1.1 1.2 Heidrich B, Manns MP, Wedemeyer H (2013). "Treatment options for hepatitis delta virus infection". Curr Infect Dis Rep. 15 (1): 31–8. doi:10.1007/s11908-012-0307-z. PMID 23242761.
- ↑ 2.0 2.1 Wedemeyer H, Manns MP (2010). "Epidemiology, pathogenesis and management of hepatitis D: update and challenges ahead". Nat Rev Gastroenterol Hepatol. 7 (1): 31–40. doi:10.1038/nrgastro.2009.205. PMID 20051970.
- ↑ Hughes SA, Wedemeyer H, Harrison PM (2011). "Hepatitis delta virus". Lancet. 378 (9785): 73–85. doi:10.1016/S0140-6736(10)61931-9. PMID 21511329.
- ↑ Samuel D, Zignego AL, Reynes M, Feray C, Arulnaden JL, David MF; et al. (1995). "Long-term clinical and virological outcome after liver transplantation for cirrhosis caused by chronic delta hepatitis". Hepatology. 21 (2): 333–9. PMID 7843702.
- ↑ Smedile A, Casey JL, Cote PJ, Durazzo M, Lavezzo B, Purcell RH; et al. (1998). "Hepatitis D viremia following orthotopic liver transplantation involves a typical HDV virion with a hepatitis B surface antigen envelope". Hepatology. 27 (6): 1723–9. doi:10.1002/hep.510270636. PMID 9620349.